The European Society for Medical Oncology (ESMO) has chosen Pasi A. Jänne, MD, PhD, to receive the ESMO Translational Research Award for changing the treatment paradigm of lung cancer.
The ESMO Translational Research Award commends scientists who are internationally recognised for their outstanding achievements in translational research. Jänne is Director of the Lowe Center for Thoracic Oncology and Director of the Belfer Center for Applied Cancer Science at the Dana-Farber Cancer Institute. He is also a Professor of Medicine at Harvard Medical School.
Jänne’s research combines laboratory-based studies with translational research and clinical trials of novel therapeutic agents in patients with lung cancer. His main research interests focus on understanding and translating the therapeutic importance of oncogenic alterations in lung cancer.
“Jänne’s investigations made him one of the co-discoverers of EGFR mutations, which changed the treatment paradigm of lung cancer and, subsequently, to the approval of the selective EGFR inhibitor osimertinib,” said Evandro de Azambuja, Chair of the ESMO Fellowship and Award Committee. “Cancer research can only evolve with people like Jänne.”
“I am both thrilled and honoured to be receiving this prestigious award from ESMO,” said Jänne. “I have had the pleasure to work with an amazing group of collaborators and colleagues and the privilege to treat and study patients with lung cancer. Without them it would not have been possible to bring our laboratory observations to the clinic and to evaluate their impact on the outcome of lung cancer patients.”
“This award provides both inspiration and energy to continue our quest to develop new and novel therapeutic approaches in our fight against lung cancer. Furthermore, it is a recognition that studying precision therapies in lung cancer can impact and inform analogous approaches across other cancers,” Jänne said.
The ESMO Translational Research Award will be presented to Jänne during the ESMO 2018 Congress on October 19 in Munich.